UBS Upgrades QuidelOrtho to Neutral, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
UBS analyst John Sourbeer has upgraded QuidelOrtho (NASDAQ:QDEL) from Sell to Neutral and increased the price target from $42 to $50.
September 19, 2024 | 7:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has upgraded QuidelOrtho from Sell to Neutral, with a new price target of $50, up from $42. This suggests a more positive outlook on the stock.
The upgrade from Sell to Neutral by UBS indicates a shift in sentiment towards QuidelOrtho, suggesting that the stock may perform better than previously expected. The raised price target to $50 reflects this improved outlook, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100